Amphista Therapeutics, a spin out of Advent Life Sciences, is a biotech company developing drugs to bring life-changing medicines to patients. Powered by transformational science we are advancing beyond traditional degrader approaches.
Amphista Therapeutics was built on groundbreaking science from the laboratory of Professor Alessio Ciulli (University of Dundee), a world leader in the field of targeted protein degradation.
Amphista Therapeutics was founded in in 2017 and is based in Chapelhall, Motherwell, United Kingdom.
Amphista Therapeutics' pipeline of novel small molecules that cause targeted protein degradation (TPD) is focused on challenging diseases including cancer. It instruct the cell to degrade the target directly rather than activating or inhibiting the target protein function.
Amphista's platform is independent of traditional E3 ubiquitin ligases used by the field, potentially expanding the available target scope of TPD approaches and should overcome recently identified PROTAC® resistance mechanisms.
Amphista Therapeutics raised $7.5M in a Series A round on April 07, 2020. The investment was led by Advent Life Sciences, alongside with Scottish Investment Bank, Scottish Growth Scheme, European Investment Fund, and BioMotiv.